GADOBENATE DIMEGLUMINE
Oligometastatic Disease
University of Colorado, DenverSmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Oligometastatic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eovist University of Colorado, Denver | Phase 4 | B |
Eloxatin University of Cologne | Phase 2 | CCC |
FLUOROURACILUM UMC Utrecht | Phase 2 | CCC |
PREDNISONE TABLETS University of Michigan Rogel Cancer Center | Phase 2 | CCC |
Tislelizumab Peking University Cancer Hospital & Institute | Phase 2 | CCC |
View all 20 →
Same molecule, other indications
GADOBENATE DIMEGLUMINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →